This result strengthens the hypothesis that patients receiving immune checkpoint inhibitors would benefit from pretreatment with NHT, such as abiraterone and enzalutamide, as they harbour more hypofunctional CD8+ T-cells in the tumour areas. This evidence concerns the gene CD8A and neoplasm.